Fri 15'th Jun 2018
Juniper Pharmaceuticals Stock Analysis
Technical stock analysis for Fri 15'th Jun 2018
Juniper Pharmaceuticals fell by -1.69% in the last day from $8.90 to $8.75 and has now fallen 5 days in a row. The price has been going up and down for this period, and there has been a -1.69% loss for the last 2 weeks. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -27 220 shares and in total 47 793 shares bought and sold for approximately $0.00.
|Shorts||2.55% ( 2018-05-31 )|
Juniper Pharmaceuticals lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -20.83% during the next 3 months and, with 90% probability hold a price between $4.94 and $8.13 at the end of this period.
Juniper Pharmaceuticals holds a sales signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $9.11. On a fall, the stock will find some support from the long-term average at approximately $8.74. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sales signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sales signal was issued from a pivot top point on Monday June 11, 2018, which indicates further falls until a new bottom pivot has been found. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.
Relative Strength Index (RSI)
RSI14 is 46 and the stock is currently not being overbought or oversold
Support & Resistance
Juniper Pharmaceuticals finds support from accumulated volume at $8.70.
In general the stock tends to have controlled movements, but the low liquidity has increased the risk substantially.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
Very Low Low Medium High Very High
Trade JNP CFDs with Plus500
Your capital is at risk.
Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).
Access these features
Auto portfolios gaining up to 30%
Top 5 Candidates in all Lists
Ultimate List Builder